Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Post by FactFinder1994on Apr 26, 2022 1:44pm
128 Views
Post# 34632843

Canada’s procurement of COVID-19 rapid test

Canada’s procurement of COVID-19 rapid test

COVID-19 testing technologies are advancing as the pandemic continues. The Government of Canada continues to pursue agreements to procure rapid tests for provinces and territories, northern and Indigenous communities, and federal organizations.

On this page

Rapid test agreements

Numbers current as of: March 17, 2022

Public Services and Procurement Canada (PSPC), on behalf of the Public Health Agency of Canada, has purchased millions of point-of-care and antigen rapid tests. These agreements help to increase COVID-19 testing capacity with authorized, proven and effective technologies. PSPC has put in place contracts for the procurement of rapid tests totaling $4 billion.

The table below outlines Canada’s agreements with suppliers for rapid tests. These tests have been procured to fulfil immediate, emerging and long-term requirements. Suppliers deliver rapid tests based on the schedule outlined in each specific contract. Canada continues to receive shipments of rapid tests on a regular basis.

Rapid test agreements with suppliers 
Supplier Name of test Tests procured
Abbott Rapid Diagnostics ULC ID NOW and Panbio tests 142,979,600
Artron COVID-19 Antigen tests 27,699,530
BD (Becton, Dickinson and Company) BD Veritor SARS-CoV-2 antigen tests 12,256,300
Biomrieux Canada RP2.1 Diagnostic test kits 224,490
BTNX Rapid Response tests 316,550,000
CanAm SD Biosensor tests 1,663,700
Cepheid GeneXpert rapid tests 1,452,980
Lucira Health Check It COVID-19 test kits 264,248
Precision Compounds COVID-19 Antigen Rapid Test Device (COV-S23) 3,506,000
Quidel QuickVue and Sofia tests 17,350,000
Hoffmann - La Roche SD Biosensor tests 11,250,000
Switch Health Holdings SD Biosensor tests 60,350,000
Trimedic Assuretech tests 7,837,640
Total 603,384,488

Request for standing offer

To continue to increase national testing and screening capacity with authorized, proven and effective technologies, the Government of Canada has issued a Request for Standing Offer (RFSO) for the supply of Health Canada-authorized COVID-19 rapid tests.

On behalf of Health Canada, PSPC is establishing standing offers with qualified companies for the supply and delivery of rapid tests on an as-needed basis. These standing offers help ensure a reliable supply chain and better position the federal government to respond to increased testing demands in the future. 

Rapid tests are procured through this RFSO to meet Health Canada’s requirements. This can include tests to distribute to provinces and territories, northern and Indigenous communities, federal organizations, or other organizations for workplace screening.

This RFSO is a way of ensuring the Government of Canada can secure rapid tests for immediate needs without delay. At this time, the RFSO includes antigen rapid tests. As needs for other types of rapid tests emerge, the RFSO can be expanded to procure other types of rapid tests for the Government of Canada as well.

Types of rapid tests


<< Previous
Bullboard Posts
Next >>